Most mutant p53 targeting strategies in cancers have focused on incorporating one of three key mechanisms: reactivation of mutp53 into a WTp53-like state [55,56,57], degradation of mutp53 [58,59,60], or perturbation of mutp53’s function while reactivating WT function [61]. This evidence concerns the gene TP53 and cancer.